•  
  •  
 

Document Type

Original Research

Abstract

Objective: The aim of this study is to evaluate the safety of outpatient anticoagulation bridging following left ventricular assist device (LVAD) implantation.

Methods: This study is a retrospective, single-center cohort of adult patients who underwent LVAD implantation (HeartMate II™ or HeartMate 3™) and received warfarin and at least one dose of therapeutic enoxaparin or fondaparinux for outpatient anticoagulation bridging. The primary endpoint was the incidence of bleeding complications within one week of completing the bridging episode. Secondary endpoints included the incidence of new hemolysis or thrombosis within 30 days, INR at the time of bridge initiation, duration of anticoagulation bridge, and management of bleeding events associated with the bridging episode.

Results: Data from 155 bridging episodes in 44 patients were analyzed. The primary endpoint occurred 30 times during 26 encounters. Of these events, 14 systemic bleeding episodes (9.03%) occurred. Localized bleeding complications consisted of injection site adverse reactions, including bruising (7.74%), bleeding (1.94%), and hematomas (0.65%). The majority of bleeding episodes were successfully self-managed by the patient and required monitoring only (83.33%). Only one new hemolysis event occurred (0.65%) and no new thrombotic events occurred within 30 days of any bridging episode.

Conclusion: Results of this study suggest that outpatient anticoagulation bridging in the LVAD patient population is associated with a moderate risk of localized bleeding and warrants careful follow-up monitoring.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

VAD_author_agreement.pdf (238 kB)
VAD_author_agreement.pdf

Share

COinS